This argument is supported by Parket al. 10, who reported that TTFs-induced inflammatory action is via the p38 MAPK/NF-kB signaling pathway and they believe that AC-EF based tumor therapy is a novel anticancer modality. The gene discussed is NFKB1; the disease is neoplasm.